padcev
astellas pharma europe b.v. - enfortumab vedotin - carcinoma, transitional cell; urologic neoplasms - antineoplastična sredstva - padcev as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor 1 or programmed death ligand 1 inhibitor.
kanuma
alexion europe sas - sebelipaza alfa - lipidna metabolizem, urogenitalne napake - drugi zdravljene bolezni prebavil in presnove izdelki, - kanuma je indiciran za dolgoročno encimsko nadomestno terapijo (ert) pri bolnikih vseh starosti z lizosomsko kislinsko lipazo (lal).
tysabri
biogen netherlands b.v. - natalizumab - multiple skleroza - selektivni imunosupresivi - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 in 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.
rituzena (previously tuxella)
celltrion healthcare hungary kft. - rituksimab - lymphoma, non-hodgkin; microscopic polyangiitis; leukemia, lymphocytic, chronic, b-cell; wegener granulomatosis - antineoplastična sredstva - rituzena je navedeno v odraslih za naslednje indikacije:ne-hodgkinova limfomi (nhl)rituzena je primerna za zdravljenje predhodno nezdravljenih bolnikov s fazo iii iv folikularni limfom v kombinaciji s kemoterapijo. rituzena monotherapy je indiciran za zdravljenje bolnikov z faza iii iv folikularni limfom, ki so kemo odporne ali so v drugi ali poznejši ponovitve po kemoterapijo. rituzena je indiciran za zdravljenje bolnikov z cd20 pozitivni razpršenih velika b celic, ki niso hodgkinova limfom v kombinaciji z chop (ciklofosfamid, doxorubicin, vincristine, prednizolon) kemoterapijo. kronično limfocitno levkemijo (cll)rituzena v kombinaciji s kemoterapijo je indiciran za zdravljenje bolnikov z predhodno nezdravljenih in relapsed/ognjevzdržni cll. samo omejeni so na voljo podatki o učinkovitosti in varnosti za bolnike predhodno zdravljenih z monoklonalna protitelesa, vključno z rituzenaor bolnikov, ognjevzdržni, da prejšnji rituzena plus kemoterapijo. granulomatosis z polyangiitis in mikroskopsko polyangiitisrituzena, v kombinaciji z glucocorticoids, je primerna za indukcijo remisije pri odraslih bolnikih s hudo, aktivno granulomatosis z polyangiitis (wegener) (gpa) in mikroskopsko polyangiitis (mpa).
vumerity
biogen netherlands b.v. - diroximel fumarate (biib098) - multiplo sklerozo, recidivno-nakazila - imunosupresivi - vumerity is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (see section 5. 1 for important information on the populations for which efficacy has been established).
tyruko
sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunosupresivi - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 in 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.
firazyr
takeda pharmaceuticals international ag - ikatibant - angioedem, dedno - srčna terapija - zdravilo firazyr je indicirano za simptomatsko zdravljenje akutnih napadov dednega angioedema (hae) pri odraslih (s pomanjkanjem inhibitorja c1-esteraze).
icatibant accord
accord healthcare s.l.u. - icatibant acetate - angioedem, dedno - other hematological agents - icatibant accord is indicated for symptomatic treatment of acute attacks of hereditary angioedema (hae) in adults, adolescents and children aged 2 years and older, with c1 esterase inhibitor deficiency.
azilect
teva b.v. - razagilin - parkinsonova bolezen - anti-parkinsonska zdravila - azilect je indiciran za zdravljenje idiopatske parkinsonove bolezni (pd) kot samostojno zdravljenje (brez levodope) ali kot dodatno zdravljenje (z levodopo) pri bolnikih z nihanji na koncu odmerka.
constella
abbvie deutschland gmbh & co. kg - linaklotid - sindrom razdražljivega črevesa - zdravila za zaprtje - constella je indicirana za simptomatsko zdravljenje zmernega do hudega sindroma razdražljivega črevesja z zaprtjem (ibs-c) pri odraslih.